Loading video...

Video Failed to Load

Go Home

8. Nvidia announces drug discovery using AI with BioNeMo NIMs

rowancheung's profile picture

Rowan Cheung

594,215 subscribers

277,760 views • 2 years ago •via X (Twitter)

Health & WellnessScience & Technology
LIVE

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Walk the #BIO2026 show floor with Kimberly Powell, NVIDIA VP of Healthcare, as she shares what’s exciting about the latest BioNeMo toolkit announcement. BioNeMo is helping bring AI-driven biology and drug discovery closer to the next experiment, with tools for researchers and developers to build, customize and deploy AI applications across the life sciences ecosystem.
1:37

Walk the #BIO2026 show floor with Kimberly Powell, NVIDIA VP of Healthcare, as she shares what’s exciting about the latest BioNeMo toolkit announcement. BioNeMo is helping bring AI-driven biology and drug discovery closer to the next experiment, with tools for researchers and developers to build, customize and deploy AI applications across the life sciences ecosystem.

NVIDIA

45,520 views • 3 months ago

AI is transforming drug discovery, enabling faster breakthroughs that lead to better patient outcomes. With Dell AI Factory with @NVIDIA you can simplify the adoption of cutting-edge technology needed to drive these advancements, with solutions tailored to you needs.
0:30

AI is transforming drug discovery, enabling faster breakthroughs that lead to better patient outcomes. With Dell AI Factory with @NVIDIA you can simplify the adoption of cutting-edge technology needed to drive these advancements, with solutions tailored to you needs.

Dell Technologies

5,591,207 views • 5 months ago

ReaSyn is helping to revolutionize drug discovery 🔬 Our new generative AI predicts synthetic pathways for molecules using step-by-step reasoning accelerating drug discovery and scientific breakthroughs. Read more and try the code ➡️ #NVIDIAResearch
0:38

ReaSyn is helping to revolutionize drug discovery 🔬 Our new generative AI predicts synthetic pathways for molecules using step-by-step reasoning accelerating drug discovery and scientific breakthroughs. Read more and try the code ➡️ #NVIDIAResearch

NVIDIA AI Developer

25,517 views • 1 year ago

🤝 Alphabet and NVIDIA are expanding their decade-long partnership to advance agentic AI, robotics, drug discovery, and more. This involves deep co-engineering with integrated platforms, open-source frameworks, and managed services. ✅ Google Cloud is one of the first to bring the NVIDIA Blackwell platform to the cloud. ✅ Google Distributed Cloud using NVIDIA Confidential Computing on #NVIDIABlackwell for enterprises to run Google Gemini on-premises. ✅ Integration of the NVIDIA AI platform across Vertex AI, Cluster Director and Google Kubernetes Engine. ✅ Bringing the NVIDIA Nemotron family of open models to Vertex AI Model Garden. Watch the full video to learn more ➡️
0:30

🤝 Alphabet and NVIDIA are expanding their decade-long partnership to advance agentic AI, robotics, drug discovery, and more. This involves deep co-engineering with integrated platforms, open-source frameworks, and managed services. ✅ Google Cloud is one of the first to bring the NVIDIA Blackwell platform to the cloud. ✅ Google Distributed Cloud using NVIDIA Confidential Computing on #NVIDIABlackwell for enterprises to run Google Gemini on-premises. ✅ Integration of the NVIDIA AI platform across Vertex AI, Cluster Director and Google Kubernetes Engine. ✅ Bringing the NVIDIA Nemotron family of open models to Vertex AI Model Garden. Watch the full video to learn more ➡️

NVIDIA AI Infrastructure

268,567 views • 8 months ago

Nvidia announces Stable Diffusion Models Accelerated with NVIDIA TensorRT featuring a1111 Gradio demo demo:
1:22

Nvidia announces Stable Diffusion Models Accelerated with NVIDIA TensorRT featuring a1111 Gradio demo demo:

AK

112,490 views • 2 years ago

Deepset helps companies move from gen AI prototypes to production fast. Through collaboration with AWS, deepset, makers of Haystack co-develops solutions aligned with the AWS gen AI strategy, helping organizations operationalize AI with speed and reliability. As part of the NVIDIA Inception Program, Deepset uses GPU-powered EC2 instances and NVIDIA NIMS components to build scalable, high-performance applications.
1:45

Deepset helps companies move from gen AI prototypes to production fast. Through collaboration with AWS, deepset, makers of Haystack co-develops solutions aligned with the AWS gen AI strategy, helping organizations operationalize AI with speed and reliability. As part of the NVIDIA Inception Program, Deepset uses GPU-powered EC2 instances and NVIDIA NIMS components to build scalable, high-performance applications.

AWS Startups

2,698,620 views • 3 months ago

• Countdown To Terafab Project • NVIDIA Announces Space-Based AI Chips In Works • Orbital Data Centers WILL Happen (Elon Was Right) • More Dinosaurs Partner With NVIDIA On “Robotaxi Ready Platform”
13:09

• Countdown To Terafab Project • NVIDIA Announces Space-Based AI Chips In Works • Orbital Data Centers WILL Happen (Elon Was Right) • More Dinosaurs Partner With NVIDIA On “Robotaxi Ready Platform”

stevenmarkryan

15,072 views • 6 months ago

France is bolstering its national #AI strategy with NVIDIA infrastructure. AI-native companies and researchers are driving development across industries and higher education using NVIDIA software and accelerated computing. Read more: #GTCParis #VivaTech
1:45

France is bolstering its national #AI strategy with NVIDIA infrastructure. AI-native companies and researchers are driving development across industries and higher education using NVIDIA software and accelerated computing. Read more: #GTCParis #VivaTech

NVIDIA

38,603 views • 1 year ago

This is WILD! Nvidia just launched something that could compress the most expensive process in medicine from 12 years to 12 months. BioNeMo Agent Toolkit is an open, agent-ready platform that turns AI agents into autonomous scientific workers, giving them the ability to run real drug discovery workflows instead of just generating ideas. And more than 50 companies are already using it, including Anthropic, OpenAI, Eli Lilly, Databricks, Snowflake, Dassault Systèmes and Schrödinger. Here is what it actually does. Traditional drug discovery costs an average of $2.6 billion per drug and takes over a decade. Most of that time and money goes into screening millions of compounds, designing proteins that bind to disease targets and running countless lab experiments to validate whether something works. BioNeMo agents now do all of that computationally before a single lab experiment begins. The demo Nvidia shared makes the speed impossible to ignore. An agent was asked to design 10 protein binders for PD-L1, a critical cancer immunotherapy target and it completed the full design, co-folding, scoring, and 3D structural analysis on GPU in under 90 seconds. What used to require weeks of wet lab work and PhD-level expertise now runs as a callable tool inside an AI workflow. The four core capabilities are virtual drug screening, protein binder design, genomic analysis, and medical imaging each one compressing tasks that previously took weeks into minutes. The institutional validation behind this is unusually strong. Nvidia and Eli Lilly announced a joint investment of up to $1 billion over five years to build a co-innovation lab running entirely on BioNeMo. The University of Washington's Institute for Protein Design is already running RosettaFold3 at 2x faster performance than the prior generation. And the market this unlocks is enormous, and Nvidia is sitting right at the center of it. The AI drug discovery market is projected to grow from $2.9 billion in 2026 to $13.8 billion by 2033 and McKinsey estimates generative AI could deliver $60 to $110 billion in annual economic value to pharma. Bullish on drug discovery!
0:36

This is WILD! Nvidia just launched something that could compress the most expensive process in medicine from 12 years to 12 months. BioNeMo Agent Toolkit is an open, agent-ready platform that turns AI agents into autonomous scientific workers, giving them the ability to run real drug discovery workflows instead of just generating ideas. And more than 50 companies are already using it, including Anthropic, OpenAI, Eli Lilly, Databricks, Snowflake, Dassault Systèmes and Schrödinger. Here is what it actually does. Traditional drug discovery costs an average of $2.6 billion per drug and takes over a decade. Most of that time and money goes into screening millions of compounds, designing proteins that bind to disease targets and running countless lab experiments to validate whether something works. BioNeMo agents now do all of that computationally before a single lab experiment begins. The demo Nvidia shared makes the speed impossible to ignore. An agent was asked to design 10 protein binders for PD-L1, a critical cancer immunotherapy target and it completed the full design, co-folding, scoring, and 3D structural analysis on GPU in under 90 seconds. What used to require weeks of wet lab work and PhD-level expertise now runs as a callable tool inside an AI workflow. The four core capabilities are virtual drug screening, protein binder design, genomic analysis, and medical imaging each one compressing tasks that previously took weeks into minutes. The institutional validation behind this is unusually strong. Nvidia and Eli Lilly announced a joint investment of up to $1 billion over five years to build a co-innovation lab running entirely on BioNeMo. The University of Washington's Institute for Protein Design is already running RosettaFold3 at 2x faster performance than the prior generation. And the market this unlocks is enormous, and Nvidia is sitting right at the center of it. The AI drug discovery market is projected to grow from $2.9 billion in 2026 to $13.8 billion by 2033 and McKinsey estimates generative AI could deliver $60 to $110 billion in annual economic value to pharma. Bullish on drug discovery!

Milk Road AI

23,215 views • 3 months ago

.Peptone is a biotech company that uses NVIDIA GPUs on AWS infrastructure for AI-driven drug discovery. They are working towards the goal of developing drugs against not only tumors but also inflammatory diseases and neurodegenerative diseases. AWS cloud operations. The ability to scale from zero to hundreds of GPUs in a matter of minutes. NVIDIA's reliability, availability, and cost of GPUs. All aiding Peptone in AI-driven drug discovery.
1:39

.Peptone is a biotech company that uses NVIDIA GPUs on AWS infrastructure for AI-driven drug discovery. They are working towards the goal of developing drugs against not only tumors but also inflammatory diseases and neurodegenerative diseases. AWS cloud operations. The ability to scale from zero to hundreds of GPUs in a matter of minutes. NVIDIA's reliability, availability, and cost of GPUs. All aiding Peptone in AI-driven drug discovery.

AWS Startups

2,166,706 views • 3 months ago

🍃 🧬 Basecamp Research is unlocking nature’s blueprint to accelerate breakthroughs in drug discovery, R&D, and beyond. With #AI accelerated by Microsoft Azure and NVIDIA, they’re creating one of the world’s largest biological databases—fueling scientific innovation across industries. 🎥Watch the series to see how #AI is solving global challenges:
1:00

🍃 🧬 Basecamp Research is unlocking nature’s blueprint to accelerate breakthroughs in drug discovery, R&D, and beyond. With #AI accelerated by Microsoft Azure and NVIDIA, they’re creating one of the world’s largest biological databases—fueling scientific innovation across industries. 🎥Watch the series to see how #AI is solving global challenges:

NVIDIA AI

29,971 views • 1 year ago

The next frontier of biology is AI-powered. Watch @Illumina CEO Jacob Thaysen explain how combining AI with genomics and proteomics will transform drug discovery, along with disease diagnosis and prevention.
0:38

The next frontier of biology is AI-powered. Watch @Illumina CEO Jacob Thaysen explain how combining AI with genomics and proteomics will transform drug discovery, along with disease diagnosis and prevention.

AMD

11,903 views • 8 months ago

The ambition at Isomorphic Labs is immense – they’re rethinking drug discovery from the ground up, using AI. 💊 Join Head of Medicinal Drug Design rebecca paul & Chief AI Officer Max Jaderberg as they share the possibilities of AI in tackling disease with host Hannah Fry. Watch their conversation ↓ Timecodes: 00:00 Intro 02:11 AI & Disease 05:30 AI in Biology 06:51 Molecules and Proteins 12:05 AlphaFold 3 14:40 Demo 16:20 Human-AI collaboration 24:30 Drug Design Challenges 39:00 Beyond Animal Models 44:35 AI Drug Future 46:30 Outro
47:07

The ambition at Isomorphic Labs is immense – they’re rethinking drug discovery from the ground up, using AI. 💊 Join Head of Medicinal Drug Design rebecca paul & Chief AI Officer Max Jaderberg as they share the possibilities of AI in tackling disease with host Hannah Fry. Watch their conversation ↓ Timecodes: 00:00 Intro 02:11 AI & Disease 05:30 AI in Biology 06:51 Molecules and Proteins 12:05 AlphaFold 3 14:40 Demo 16:20 Human-AI collaboration 24:30 Drug Design Challenges 39:00 Beyond Animal Models 44:35 AI Drug Future 46:30 Outro

Google DeepMind

78,088 views • 1 year ago

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.
1:36

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.

vitrupo

157,146 views • 1 year ago

Nvidia CEO Jensen Huang announces GM has partnered with Nvidia to build its self-driving car fleet: "The time for autonomous vehicles has arrived."
1:11

Nvidia CEO Jensen Huang announces GM has partnered with Nvidia to build its self-driving car fleet: "The time for autonomous vehicles has arrived."

Yahoo Finance

17,276,812 views • 1 year ago

"The future is really bright in AI and drug discovery." Sean McClain, Founder and CEO of Absci, shared the CES stage with healthcare leaders to illustrate how the compute partnership with AMD has scaled their ability to screen over a million drugs in one single day, resulting in better models for drug discovery.
1:14

"The future is really bright in AI and drug discovery." Sean McClain, Founder and CEO of Absci, shared the CES stage with healthcare leaders to illustrate how the compute partnership with AMD has scaled their ability to screen over a million drugs in one single day, resulting in better models for drug discovery.

AMD

15,346 views • 8 months ago